FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to a liquid pharmaceutical composition comprising pegilated erythropoietin as a conjugate in pharmaceutically acceptable buffer at pH from 5.5 to 7.0 and optionally one or some pharmaceutically acceptable excipients. Proposed composition is used in treatment and prophylaxis of diseases associated with erythropoiesis injury. The advantage of invention involves enhancing stability of the preparation.
EFFECT: improved and valuable property of preparation.
59 cl, 4 tbl, 11 dwg, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATES OF ERYTHROPOIETIN AND POLYETHYLENE GLYCOL, PHARMACEUTICAL COMPOSITIONS (VARIANTS), METHOD FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF DISTURBANCES AND METHOD FOR PREPARING CONJUGATE OR COMPOSITION | 2000 |
|
RU2232163C2 |
| ERYTHROPOETIN APPLICATION | 2003 |
|
RU2305554C2 |
| NEW APPLICATION OF ERYTHROPOIETIN IN HEART DISEASES | 2003 |
|
RU2324494C2 |
| PEG-CONTAINING CONJUGATES OF HGF-NK4 | 2002 |
|
RU2293574C2 |
| PURIFICATION OF PEGYLATED POLYPEPTIDES | 2008 |
|
RU2476439C2 |
| NEW METHOD FOR OBTAINING LONG-ACTING DRUG CONJUGATE BY PRODUCING INTERMEDIATE | 2019 |
|
RU2805873C2 |
| MODIFIED ERYTHROPOIETIN WITH ATTACHED WATER-SOLUBLE LONG-CHAIN MOLECULE | 2010 |
|
RU2549986C2 |
| CONJUGATE OF GLYCOPROTEIN, POSSESSING ERYTHROPOIETIN ACTIVITY, WITH POLY-1,4-ETHYLENEPIPERAZINE N-OXIDE DERIVATIVES (VERSIONS), PHARMACEUTICAL COMPOSITION AND METHOD OF CONJUGATE OBTAINING | 2013 |
|
RU2556378C2 |
| IMPROVED METHOD FOR HIGH-YIELD PRODUCTION OF PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE | 2014 |
|
RU2677796C9 |
| TREATMENT OF NEURODEGENERATIVE DISORDERS | 2006 |
|
RU2467761C2 |
